Vaccines Value Evidence Lead, mRNA Development

le contenu du travail

Site Name: Belgium-Wavre

Posted Date: Jul 10 2023

About GSK R&D:

Patient-focused Research and Development (R&D) is the heart of our business. GSK has a strong history and expertise in vaccines, and we are staying at the forefront of innovation in this field. For many years, vaccines have been used mainly to prevent diseases caused by infections, mostly in infants and children. Today, we are focused on developing vaccines for all stages of life, and we believe vaccines can also be used successfully to treat diseases and therefore be therapeutic.

These innovation trends have a strong impact on what we do in Research and Development. We take the best science, with the most impactful technologies and combine it with our GSK culture. Next to our existing portfolio of prophylactic vaccines and moving into the field of therapeutic vaccines, our R&D programme focuses on vaccines for diseases such as RSV and Meningitis. Another part of R&D targets diseases particularly prevalent in the developing world, including the World Health Organisation’s priority diseases - tuberculosis and malaria.

About the Vaccines Value Evidence Team:

As part of the R&D organisation, the Vaccines Value Evidence team (Vx VE Team) drives the identification, strategic planning, and development of the value evidence requirements from early to late development and lifecycle management.

About You:

As mRNA Development Vaccines Value Evidence Lead (Director level), you are accountable for driving the Global Value Evidence Generation and project work for the GSK Curevac collaboration mRNA vaccines assets all the way to life cycle management to which matrix leadership and direct reports are deployed including line management and mentoring.

This role is essential to ensure that the Curevac mRNA Development vaccine program is supported by scientifically credible, high-quality evidence that drives competitiveness and strong evidence-based product positioning, value propositions and value-based pricing.

The role is critical for the alignment of value evidence generation with the evidentiary requirements of customers responsible for marketing authorisation, recommendation (e.g. National Immunization Technical Advisory Groups - NITAGs) and reimbursement leading to successful patient access, product use and commercial success.

This role requires leadership of a matrix team drawn from global platforms to develop the options for evidence generation requiring a strong ability to manage complex matrix relationships and interdependencies. In addition to strategic leadership, this position also facilitates alignment and visibility to the activities conducted globally, regionally and locally.

Your responsibilities:

• Lead and ensure alignment across the matrix Vx VE Team for the mRNA development assets, drawn from VEO (Real World Analytics, Patient Centric Outcomes) and other R&D platforms (epidemiology, statistics, medical affairs, regional and LOC health outcomes and market access) and potentially collaborators from Curevac to deliver the Value Evidence Generation strategic options, plans and execution which fall under the Integrated Evidence Plan (IEP) and Work Package 6 of the Integrated Asset Plan.
• Lead the external dialogue on the global scientific mRNA Development value evidence requirements with recommendation and reimbursement bodies including seeking formal scientific advice to National Immunization Technical Advisory Committees (NITAGs) and Health Technology Assessment (HTA) bodies.
• Partner with a complex set of global, regional and local internal and Curevac stakeholders including Vaccine Development Leads, Global Vaccine Commercial Leads, Epidemiology and Clinical Scientists, global and local Medical Affairs, local Market Access within GSK etc. and ensure appropriate representation at project governance level (VDT, VCT, SEAS).
• Lead, manage, and develop direct reports to develop high quality value evidence strategies, optimising resources in alignment with priorities, and ensuring timely, robust execution of evidence for the mRNA development assets.
• Deliver the mRNA Development Value Evidence and Outcome materials to inform internal governance decision making (Research, Development and LCM Boards, Vaccines Investment Board, Forecast Review Committee) and support the regions and priority LOCs on recommendation and reimbursement activities.
• Lead scientific robust mRNA Development value evidence studies (e.g. cost-of-illness, resource utilisation, utility and quality of life assessments, Patient Reported Outcomes (PROs), Real World Evidence (RWE), economic and public health impact modelling, indirect study comparisons, etc) ensuring scientific robustness and compliance with necessary regulations for quality and disclosure.
• Partner with the VEO Patient Centric Outcomes and VEO Real World Analytics teams to ensure the operational delivery of Patient Reported Outcomes (PROs) and Real World Evidence (RWE) aligned with the Target vaccine Profile expectations.
• Lead annual mRNA Development EPE and IPE forecasting and activity prioritisation while effectively managing projects and budgets for Human Subject Research (HSR) and non-HSR activities.
• Develop and maintain excellent network contacts with industry associations, professional societies and external Health Economics and Public Health experts / thought leaders to keep abreast and bring GSK’s perspective to significant developments in the field.
• Integrate excellent understanding of the evolving global NITAG, Health Technology Assessment, policy decision maker and payer environment, including recommendation, reimbursement, pricing, and access.
  
  

Why you?

Basic Qualifications:

We are looking for professionals with these required skills to achieve our goals:

• Minimum 8 years of proven and successful experience in Health Economics, Health Outcomes, Market Access or an aligned discipline / function in a consulting, pharmaceutical industry or academic environment.
• Experience in negotiating with payers and / or public health authorities leading to successful recommendations and reimbursement in multiple markets preferably in the Vaccines field.
• Pharmaceutical experience that includes: 1) Above country experience; 2) Effective leadership leading cross-functional teams to deliver an integrated plan and driving consensus decision making.
• Authored publications in infectious diseases and / or vaccines value evidence discipline.
  
  

Preferred Qualifications:

If you have the following characteristics it would be a plus:

• Experience in Covid 19 Therapeutics / Vaccines
• PhD in a relevant discipline
• Higher business or management qualification In Business, Health Sciences.
  
  

If you have a disability and require assistance during the course of the selection process, you will have the opportunity to let us know what specific assistance you require in order to make suitable arrangements.

GSK is a global biopharma company with a special purpose – to unite science, technology and talent to get ahead of disease together – so we can positively impact the health of billions of people and deliver stronger, more sustainable shareholder returns – as an organisation where people can thrive. Getting ahead means preventing disease as well as treating it, and we aim to positively impact the health of 2.5 billion people by the end of 2030.

Our success absolutely depends on our people. While getting ahead of disease together is about our ambition for patients and shareholders, it’s also about making GSK a place where people can thrive. We want GSK to be a workplace where everyone can feel a sense of belonging and thrive as set out in our Equal and Inclusive Treatment of Employees policy. We’re committed to being more proactive at all levels so that our workforce reflects the communities we work and hire in, and our GSK leadership reflects our GSK workforce.

Important notice to Employment businesses/ Agencies

GSK does not accept referrals from employment businesses and/or employment agencies in respect of the vacancies posted on this site. All employment businesses/agencies are required to contact GSK’s commercial and general procurement/human resources department to obtain prior written authorization before referring any candidates to GSK. The obtaining of prior written authorization is a condition precedent to any agreement (verbal or written) between the employment business/ agency and GSK. In the absence of such written authorization being obtained any actions undertaken by the employment business/agency shall be deemed to have been performed without the consent or contractual agreement of GSK. GSK shall therefore not be liable for any fees arising from such actions or any fees arising from any referrals by employment businesses/agencies in respect of the vacancies posted on this site.